Acimtamig is a monoclonal antibody commercialized by Affimed, with a leading Phase II program in Anaplastic Large Cell Lymphoma (ALCL). According to Globaldata, it is involved in 6 clinical trials, which were completed. GlobalData uses proprietary data and analytics to provide a complete picture of Acimtamig’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Acimtamig is expected to reach an annual total of $140 mn by 2038 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Acimtamig Overview
AFM-13 is under development for the treatment of refractory and relapsed Hodgkin lymphoma, CD30+ lymphoma such as transformed mycosis fungoides, peripheral and cutaneous T-cell lymphoma, angioimmunoblastic T cell lymphoma, large B-cell lymphoma, B-cell non-Hodgkin lymphoma, Hodgkin lymphoma combination with check point inhibitors and Hodgkin lymphoma combination with lenalidomide. The drug candidate is administered intravenously. AFM-13 is a bi-specific, tetravalent human antibody, it acts by targeting CD30/CD16A.
Affimed Overview
Affimed, is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. It develops pipeline products for the treatment of cancers. The pipleline products includes AFM24-203+ Adoptive NK Cells, AFM13-104+Adoptive NK Cells to treat certain CD30-positive (CD30+) cancers. AFM24-101 Monotherapy, AFM24-102+ANTI-PD-L1, AFM24-103 and Adoptive NK Cells, AFVT-2101 (AFM32) targets solid tumors. AFM28-101 Monotherapy, AFM28 + Adoptive NK Cells is for the treatment of acute myeloid leukemia (AML). AFM13-103 + Anti-PD-1 treats hodgkin lymphoma. AFM13-202 Monotherapy treats peripheral T cell lymphoma. Affimed is headquartered in Heidelberg, Baden-Wurttemberg, Germany.
The company reported revenues of (Euro) EUR8.3 million for the fiscal year ended December 2023 (FY2023), a decrease of 80% over FY2022. The operating loss of the company was EUR106.7 million in FY2023, compared to an operating loss of EUR88.1 million in FY2022. The net loss of the company was EUR105.9 million in FY2023, compared to a net loss of EUR86 million in FY2022.
The company reported revenues of EUR0.2 million for the first quarter ended March 2024, a decrease of 62.5% over the previous quarter.
For a complete picture of Acimtamig’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
